Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMIT trial in stage III melanoma with major pathologic response after neoadjuvant nivolumab + ipilimumab
NL-OMON57418Recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab and ipilimumab in melanoma, sponsored by Erasmus MC. Primary endpoints: 2-year locoregional recurrence-free survival and 2-year distant metastasis-free survival. Started Apr 2025; status: recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON57418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57418.